Cite
1054P A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors.
MLA
Qin, S., et al. “1054P A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Modular CLDN18.2-Targeting PG CAR-T Therapy (IBI345) in Patients with CLDN18.2+ Solid Tumors.” Annals of Oncology, vol. 34, Oct. 2023, p. S638. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2193.
APA
Qin, S., Tian, W., Li, M., Wei, H., Sun, L., Xie, Q., Lin, E., Xu, D., Tian, J., Chen, J., Lu, W., Gao, N., Chen, L., Duo, J., Ye, L., Cheng, T., Sui, Y., Klein, C., & Chen, W. (2023). 1054P A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors. Annals of Oncology, 34, S638. https://doi.org/10.1016/j.annonc.2023.09.2193
Chicago
Qin, S., W. Tian, M. Li, H. Wei, L. Sun, Q. Xie, E. Lin, et al. 2023. “1054P A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Modular CLDN18.2-Targeting PG CAR-T Therapy (IBI345) in Patients with CLDN18.2+ Solid Tumors.” Annals of Oncology 34 (October): S638. doi:10.1016/j.annonc.2023.09.2193.